hydroxyurea

Crizanlizumab helps prevent pain crises in sickle cell diseaseIn patients with sickle cell disease, therapy with crizanlizumab, an antibody against the adhesion molecule P-selectin, resulted in a significantly lower rate of sickle cell-related pain crises than placebo, a trial in 198 patients aged from 16 to 65 years showed.
FDA approves first drug to treat patients with a chronic type of bone marrow diseaseFDA approved a new use for ruxolitinib (Jakafi, Incyte) to treat patients with polycythemia vera (PV), a chronic type of bone marrow disease. Jakafi is the first drug approved by FDA for this condition.
New treatment guidelines for sickle cell diseaseExpand treatment of sickle cell disease with 2 “underused” preventive therapies to reduce painful flare-ups, an expert panel convened by the National Heart, Lung, and Blood Institute urges in new management guidelines.